PHILADELPHIA, /CSRwire/ – Teva Pharmaceutical Industries Ltd., (NYSE: TEVA) today announced the U.S. organizations selected as part of Teva’s 2016 Community Partnership Program. Now in its fifth year, this exciting Teva program provides charitable funding and employee volunteers to qualified local organizations that support patients and their caregivers in geographic areas where Teva has business presence.
Teva is the proud recipient of two prestigious 2015 Corporate Social Responsibility Awards honoring both the Community Partnership Program as well as the Volunteers in Medicine program that assists communities in developing free healthcare clinics for America’s uninsured.
“Through our Community Partnership Program, Teva is committed to improving the overall health of our communities where we live and work and share our goal of improving healthcare around the world,” said Denise Bradley, Senior Vice President, Global Corporate Reputation. “Working with these inspiring organizations allows us to provide meaningful assistance to patients in need.”
2016 Community Partners:
Pennsylvania (Greater Philadelphia Area)
Kansas City Area
Northern New Jersey/New York City
Salt Lake City, UT
“We are excited to partner with organizations that are committed to improving the lives of patients on a daily basis,” said Laurie Thibodeau, Senior Director, Corporate Social Responsibility. “The partnership with these organizations demonstrates Teva’s continued commitment to its patients around the world, preservation of the environment and our commitment to ensuring Teva employees can achieve their fullest potential by supporting those in need.”
To learn more about Teva’s recent innovative CSR and sustainability achievements and to access the CSR Citizenship Highlights Report, click here.
Click here to learn more about Teva’s 2016 Community Partners.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions to millions of patients every day. Headquartered in Israel, Teva is the world’s largest generic medicines producer, leveraging its portfolio of more than 1,000 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has a world-leading position in innovative treatments for disorders of the central nervous system, including pain, as well as a strong portfolio of respiratory products. Teva integrates its generics and specialty capabilities in its global research and development division to create new ways of addressing unmet patient needs by combining drug development capabilities with devices, services and technologies. Teva’s net revenues in 2014 amounted to $20.3 billion. For more information, visit tevapharm.com.